ReviewGenes & cancer2016
The liquid biopsy in lung cancer.
Review in Genes & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Update on the types and usage of liquid biopsies in the clinical setting: a systematic review.BMC cancer · 2018Pooled it
- Detection of the MYD88Annals of hematology · 2020Trial
- Rare sequential EGFR and ALK mutations in non-small cell lung cancer: A case report and literature review.Oncology letters · 2025Article
- Review
- The latest advances in liquid biopsy for lung cancer-a narrative review.Translational lung cancer research · 2024Review
- Liquid biopsy for CNS lymphoma: CSF exosomes and CSF exosomal miR-15a, miR-21, miR-155, miR-210, and miR-19b are promising biomarkers for diagnosis.Molecular biology reports · 2024Article
- Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.EXCLI journal · 2023Review
- The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Liquid biopsy in cholangiocarcinoma: Current status and future perspectives.World journal of gastrointestinal oncology · 2021Review
- Budget Impact Analysis ofDiagnostics (Basel, Switzerland) · 2020Article
- Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2019Review
- FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.Clinical and experimental medicine · 2019Article
- Feasibility of circulating tumor DNA testing in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2019Article
- Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.Molecular biology reports · 2019Article
- A guide to nucleic acid detection by single-molecule kinetic fingerprinting.Methods (San Diego, Calif.) · 2019Article
- Selecting short length nucleic acids localized in exosomes improves plasmaCancer cell international · 2019Article
- Liquid Biopsy in Thyroid Cancer: New Insight.International journal of hematology-oncology and stem cell research · 2018Review
- Liquid biopsy and its role in an advanced clinical trial for lung cancer.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- A Review of Circulating Tumor DNA in Hepatobiliary Malignancies.Frontiers in oncology · 2018Review
- Reliability of using circulating tumor cells for detecting epidermal growth factor receptor mutation status in advanced non-small-cell lung cancer patients: a meta-analysis and systematic review.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of lung cancer has significantly increased over the last century, largely due to smoking, and remains the most common cause of cancer deaths worldwide. This is often due to lung cancer first presenting at late stages and a lack of curative therapeutic options at these later stages. Delayed diagnoses, inadequate tumor sampling, and lung cancer misdiagnoses are also not uncommon due to the limitations of the tissue biopsy. Our better understanding of the tumor microenvironment and the systemic actions of tumors, combined with the recent advent of the liquid biopsy, may allow molecular diagnostics to be done on circulating tumor markers, particularly circulating tumor DNA. Multiple liquid biopsy molecular methods are presently being examined to determine their efficacy as surrogates to the tumor tissue biopsy. This review will focus on new liquid biopsy technologies and how they may assist in lung cancer detection, diagnosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.